Physician profile
Sufyan Malik
NPI 1356703573
$839.73
in general payments reported to CMS, 2019-2025
19 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.85 · 2020: $28.91 · 2021: $404 · 2022: $77.52 · 2023: $42.96 · 2024: $68.28 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $236.50 | 2021-2022 | |
| Pfizer INC. | $76.47 | 2019-2022 | |
| Lilly USA, LLC | $75.01 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $65.52 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $51.95 | 2019-2025 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $47.88 | 2021 | |
| Dexcom, INC. | $39.24 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $34.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.61 | 2021 | |
| Lundbeck LLC | $28.97 | 2025 | Vyepti |
| Abbvie INC. | $24.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.25 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $19.37 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.53 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.13 | 2025 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.81 | 2025 | Strensiq |
| Neurelis, INC. | $14.54 | 2025 | Valtoco |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2019 | |
| Merck Sharp & Dohme LLC | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sufyan Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.